Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$23.50 USD
+0.76 (3.34%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $23.51 +0.01 (0.04%) 6:48 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/04/2025
Time: -- |
9/2025 | $-0.56 | 0.00% |
Earnings Summary
For their last quarter, Stoke Therapeutics (STOK) reported earnings of -$0.40 per share, beating the Zacks Consensus Estimate of $-0.57 per share. This reflects a positive earnings surprise of 29.82%. Look out for STOK's next earnings release expected on November 04, 2025. For the next earning release, we expect the company to report earnings of -$0.56 per share, reflecting a year-over-year decrease of 19.15%.
Earnings History
Price & Consensus
Zacks News for STOK
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
STOK FAQs
Based on past history, Zacks believes Stoke Therapeutics, Inc. (STOK) will report their next quarter earnings on November 04, 2025. For the next earning release, we expect the company to report earnings of -0.56 per share, reflecting a year-over-year increase of -19.15.
Based on past history, Zacks believes Stoke Therapeutics, Inc. (STOK) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 04, 2025.
The Zacks Consensus Estimate for Stoke Therapeutics, Inc. (STOK) for the quarter ending September 2025 is $-0.56 a share. We expect Stoke Therapeutics, Inc. (STOK) to report earnings in line with the consensus estimate of $-0.56 per share
In the earnings report for the quarter ending in June 2024, Stoke Therapeutics, Inc. (STOK) announced earnings of $-0.46 per share versus the Zacks Consensus Estimate of $-0.57 per share, representing a surprise of -19.30%.